Armstrong Advisory Group’s Outlook Therapeutics OTLK Stock Holding History

Armstrong Advisory Group’s Portfolio OTLK Stock Details OTLK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$285	Hold	179	–	–	﹤0.01%	967
2026 Q1	$37	Hold	179	–	–	﹤0.01%	952
2025 Q4	$283	Hold	179	–	–	﹤0.01%	937
2025 Q3	$190	Hold	179	–	–	﹤0.01%	930
2025 Q2	$287	Hold	179	–	–	﹤0.01%	910
2025 Q1	$339	Hold	179	–	–	﹤0.01%	827
2024 Q4	$339	Hold	179	–	–	﹤0.01%	827
2024 Q3	$956	Hold	179	–	–	﹤0.01%	759
2024 Q2	$1.32K	Sell	179 -3,401	-95%	-$27.3K	﹤0.01%	750
2024 Q1	$1.41K	Buy	3,580 +3,401	+1,900%	+$27.5K	﹤0.01%	730
2023 Q4	$1.41K	Hold	179	–	–	﹤0.01%	730
2023 Q3	$792	Buy	+179	New	+$3.96K	﹤0.01%	807

Other funds holding OTLK

CKAIS

Christensen King & Associates Investment Services Richland, Washington $252M AUM 20.51% 1-Year Est. Return

FCC

Flower City Capital Pittsford, New York $227M AUM 23.31% 1-Year Est. Return

OFS

Orrstown Financial Services Harrisburg, Pennsylvania $674M AUM 23.23% 1-Year Est. Return

FTWA

Fifth Third Wealth Advisors Cincinnati, Ohio $3.58B AUM 34.55% 1-Year Est. Return

GoalVest Advisory New York $539M AUM 27.49% 1-Year Est. Return

Armstrong Advisory Group's OTLK Position: Q2 2026 in Review

Armstrong Advisory Group held its Outlook Therapeutics (OTLK) position steady in Q2 2026 at 179 shares worth $285. The position accounts for ﹤0.01% of the portfolio, ranked #967.

Armstrong Advisory Group first reported a position in OTLK in Q3 2023 and has held it in 12 quarters since. The position peaked at $1.41K in Q1 2024. 6 funds tracked by Wall St. Rank hold OTLK as of Q2 2026.

Armstrong Advisory Group held 179 shares of Outlook Therapeutics worth $285 as of Q2 2026.
Armstrong Advisory Group left its Outlook Therapeutics share count unchanged in Q2 2026.
Outlook Therapeutics made up ﹤0.01% of Armstrong Advisory Group's portfolio in Q2 2026, its #967 holding.
Armstrong Advisory Group first reported a position in Outlook Therapeutics in Q3 2023 and has held it in 12 quarters since.
Armstrong Advisory Group's Outlook Therapeutics position peaked at $1.41K in Q1 2024.
6 funds tracked by Wall St. Rank held Outlook Therapeutics as of Q2 2026.

Based on Armstrong Advisory Group's 13F filing for Q2 2026, filed 13 Jul 2026.